T-cell acute lymphoblastic leukemia (T-ALL) is a malignancy of T-cell progenitors, with overall survival rates of 70
% in children and <40
% in adults. The majority of T-ALL cases harbour activating mutations in NOTCH1, which encodes a membrane-spanning receptor essential for lineage commitment and development of T-lymphocytes. Activating NOTCH1 mutations occur in ~60% of human T-cell acute lymphoblastic leukemias (T-ALLs), and mutations disrupting the transcription factor IKZF1 (IKAROS) occur in ~5% of cases. These results demonstrate for the first time that aberrant NOTCH activity compromises IKAROS function in mouse and human T-ALL, and provide a potential explanation for the relative infrequency of IKAROS gene mutations in human T-ALL.
Reference: Witkowski MT, Cimmino L, Hu Y, Trimarchi T, Tagoh H, McKenzie MD, Best SA, Tuohey L, Willson TA, Nutt SL, Busslinger M, Aifantis I, Smyth GK,
Dickins RA. Activated Notch counteracts Ikaros tumor suppression in mouse and human T-cell acute lymphoblastic leukemia. Leukemia. 2015 Jun;29(6):1301-11. doi: 10.1038/leu.2015.27. Epub 2015 Feb 6.
No comments:
Post a Comment
Thankyou for your comment. We moderate all messages and may take a little time to review your comment. Please email inquiries to ccs.comms@monash.edu.